IBDEI1KL ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,25457,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
;;^UTILITY(U,$J,358.3,25457,1,4,0)
;;=4^T43.205A
;;^UTILITY(U,$J,358.3,25457,2)
;;=^5050540
;;^UTILITY(U,$J,358.3,25458,0)
;;=T43.205D^^92^1157^5
;;^UTILITY(U,$J,358.3,25458,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25458,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
;;^UTILITY(U,$J,358.3,25458,1,4,0)
;;=4^T43.205D
;;^UTILITY(U,$J,358.3,25458,2)
;;=^5050541
;;^UTILITY(U,$J,358.3,25459,0)
;;=T43.205S^^92^1157^6
;;^UTILITY(U,$J,358.3,25459,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25459,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Sequela
;;^UTILITY(U,$J,358.3,25459,1,4,0)
;;=4^T43.205S
;;^UTILITY(U,$J,358.3,25459,2)
;;=^5050542
;;^UTILITY(U,$J,358.3,25460,0)
;;=G25.71^^92^1157^7
;;^UTILITY(U,$J,358.3,25460,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25460,1,3,0)
;;=3^Medication-Induced Acute Akathisia
;;^UTILITY(U,$J,358.3,25460,1,4,0)
;;=4^G25.71
;;^UTILITY(U,$J,358.3,25460,2)
;;=^5003799
;;^UTILITY(U,$J,358.3,25461,0)
;;=G24.02^^92^1157^8
;;^UTILITY(U,$J,358.3,25461,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25461,1,3,0)
;;=3^Medication-Induced Acute Dystonia
;;^UTILITY(U,$J,358.3,25461,1,4,0)
;;=4^G24.02
;;^UTILITY(U,$J,358.3,25461,2)
;;=^5003785
;;^UTILITY(U,$J,358.3,25462,0)
;;=G21.0^^92^1157^12
;;^UTILITY(U,$J,358.3,25462,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25462,1,3,0)
;;=3^Neuroleptic Malignant Syndrome
;;^UTILITY(U,$J,358.3,25462,1,4,0)
;;=4^G21.0
;;^UTILITY(U,$J,358.3,25462,2)
;;=^5003771
;;^UTILITY(U,$J,358.3,25463,0)
;;=T50.905A^^92^1157^1
;;^UTILITY(U,$J,358.3,25463,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25463,1,3,0)
;;=3^Adverse Effect of Medication,Other,Init Encntr
;;^UTILITY(U,$J,358.3,25463,1,4,0)
;;=4^T50.905A
;;^UTILITY(U,$J,358.3,25463,2)
;;=^5052160
;;^UTILITY(U,$J,358.3,25464,0)
;;=T50.905S^^92^1157^2
;;^UTILITY(U,$J,358.3,25464,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25464,1,3,0)
;;=3^Adverse Effect of Medication,Other,Sequela
;;^UTILITY(U,$J,358.3,25464,1,4,0)
;;=4^T50.905S
;;^UTILITY(U,$J,358.3,25464,2)
;;=^5052162
;;^UTILITY(U,$J,358.3,25465,0)
;;=T50.905D^^92^1157^3
;;^UTILITY(U,$J,358.3,25465,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25465,1,3,0)
;;=3^Adverse Effect of Medication,Other,Subseq Encntr
;;^UTILITY(U,$J,358.3,25465,1,4,0)
;;=4^T50.905D
;;^UTILITY(U,$J,358.3,25465,2)
;;=^5052161
;;^UTILITY(U,$J,358.3,25466,0)
;;=F45.22^^92^1158^1
;;^UTILITY(U,$J,358.3,25466,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25466,1,3,0)
;;=3^Body Dysmorphic D/O
;;^UTILITY(U,$J,358.3,25466,1,4,0)
;;=4^F45.22
;;^UTILITY(U,$J,358.3,25466,2)
;;=^5003588
;;^UTILITY(U,$J,358.3,25467,0)
;;=F63.3^^92^1158^8
;;^UTILITY(U,$J,358.3,25467,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25467,1,3,0)
;;=3^Trichotillomania (Hair-Pulling D/O)
;;^UTILITY(U,$J,358.3,25467,1,4,0)
;;=4^F63.3
;;^UTILITY(U,$J,358.3,25467,2)
;;=^5003643
;;^UTILITY(U,$J,358.3,25468,0)
;;=F06.8^^92^1158^4
;;^UTILITY(U,$J,358.3,25468,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,25468,1,3,0)
;;=3^OCD & Rel D/O d/t Phys Cond
;;^UTILITY(U,$J,358.3,25468,1,4,0)
;;=4^F06.8
;;^UTILITY(U,$J,358.3,25468,2)
;;=^5003062
;;^UTILITY(U,$J,358.3,25469,0)
;;=F42.4^^92^1158^2
;;^UTILITY(U,$J,358.3,25469,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1KL 3773 printed Apr 09, 2024@20:57:33 Page 2
IBDEI1KL ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,25457,1,3,0)
+2 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
+3 ;;^UTILITY(U,$J,358.3,25457,1,4,0)
+4 ;;=4^T43.205A
+5 ;;^UTILITY(U,$J,358.3,25457,2)
+6 ;;=^5050540
+7 ;;^UTILITY(U,$J,358.3,25458,0)
+8 ;;=T43.205D^^92^1157^5
+9 ;;^UTILITY(U,$J,358.3,25458,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,25458,1,3,0)
+12 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
+13 ;;^UTILITY(U,$J,358.3,25458,1,4,0)
+14 ;;=4^T43.205D
+15 ;;^UTILITY(U,$J,358.3,25458,2)
+16 ;;=^5050541
+17 ;;^UTILITY(U,$J,358.3,25459,0)
+18 ;;=T43.205S^^92^1157^6
+19 ;;^UTILITY(U,$J,358.3,25459,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,25459,1,3,0)
+22 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
+23 ;;^UTILITY(U,$J,358.3,25459,1,4,0)
+24 ;;=4^T43.205S
+25 ;;^UTILITY(U,$J,358.3,25459,2)
+26 ;;=^5050542
+27 ;;^UTILITY(U,$J,358.3,25460,0)
+28 ;;=G25.71^^92^1157^7
+29 ;;^UTILITY(U,$J,358.3,25460,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,25460,1,3,0)
+32 ;;=3^Medication-Induced Acute Akathisia
+33 ;;^UTILITY(U,$J,358.3,25460,1,4,0)
+34 ;;=4^G25.71
+35 ;;^UTILITY(U,$J,358.3,25460,2)
+36 ;;=^5003799
+37 ;;^UTILITY(U,$J,358.3,25461,0)
+38 ;;=G24.02^^92^1157^8
+39 ;;^UTILITY(U,$J,358.3,25461,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,25461,1,3,0)
+42 ;;=3^Medication-Induced Acute Dystonia
+43 ;;^UTILITY(U,$J,358.3,25461,1,4,0)
+44 ;;=4^G24.02
+45 ;;^UTILITY(U,$J,358.3,25461,2)
+46 ;;=^5003785
+47 ;;^UTILITY(U,$J,358.3,25462,0)
+48 ;;=G21.0^^92^1157^12
+49 ;;^UTILITY(U,$J,358.3,25462,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,25462,1,3,0)
+52 ;;=3^Neuroleptic Malignant Syndrome
+53 ;;^UTILITY(U,$J,358.3,25462,1,4,0)
+54 ;;=4^G21.0
+55 ;;^UTILITY(U,$J,358.3,25462,2)
+56 ;;=^5003771
+57 ;;^UTILITY(U,$J,358.3,25463,0)
+58 ;;=T50.905A^^92^1157^1
+59 ;;^UTILITY(U,$J,358.3,25463,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,25463,1,3,0)
+62 ;;=3^Adverse Effect of Medication,Other,Init Encntr
+63 ;;^UTILITY(U,$J,358.3,25463,1,4,0)
+64 ;;=4^T50.905A
+65 ;;^UTILITY(U,$J,358.3,25463,2)
+66 ;;=^5052160
+67 ;;^UTILITY(U,$J,358.3,25464,0)
+68 ;;=T50.905S^^92^1157^2
+69 ;;^UTILITY(U,$J,358.3,25464,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,25464,1,3,0)
+72 ;;=3^Adverse Effect of Medication,Other,Sequela
+73 ;;^UTILITY(U,$J,358.3,25464,1,4,0)
+74 ;;=4^T50.905S
+75 ;;^UTILITY(U,$J,358.3,25464,2)
+76 ;;=^5052162
+77 ;;^UTILITY(U,$J,358.3,25465,0)
+78 ;;=T50.905D^^92^1157^3
+79 ;;^UTILITY(U,$J,358.3,25465,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,25465,1,3,0)
+82 ;;=3^Adverse Effect of Medication,Other,Subseq Encntr
+83 ;;^UTILITY(U,$J,358.3,25465,1,4,0)
+84 ;;=4^T50.905D
+85 ;;^UTILITY(U,$J,358.3,25465,2)
+86 ;;=^5052161
+87 ;;^UTILITY(U,$J,358.3,25466,0)
+88 ;;=F45.22^^92^1158^1
+89 ;;^UTILITY(U,$J,358.3,25466,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,25466,1,3,0)
+92 ;;=3^Body Dysmorphic D/O
+93 ;;^UTILITY(U,$J,358.3,25466,1,4,0)
+94 ;;=4^F45.22
+95 ;;^UTILITY(U,$J,358.3,25466,2)
+96 ;;=^5003588
+97 ;;^UTILITY(U,$J,358.3,25467,0)
+98 ;;=F63.3^^92^1158^8
+99 ;;^UTILITY(U,$J,358.3,25467,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,25467,1,3,0)
+102 ;;=3^Trichotillomania (Hair-Pulling D/O)
+103 ;;^UTILITY(U,$J,358.3,25467,1,4,0)
+104 ;;=4^F63.3
+105 ;;^UTILITY(U,$J,358.3,25467,2)
+106 ;;=^5003643
+107 ;;^UTILITY(U,$J,358.3,25468,0)
+108 ;;=F06.8^^92^1158^4
+109 ;;^UTILITY(U,$J,358.3,25468,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,25468,1,3,0)
+112 ;;=3^OCD & Rel D/O d/t Phys Cond
+113 ;;^UTILITY(U,$J,358.3,25468,1,4,0)
+114 ;;=4^F06.8
+115 ;;^UTILITY(U,$J,358.3,25468,2)
+116 ;;=^5003062
+117 ;;^UTILITY(U,$J,358.3,25469,0)
+118 ;;=F42.4^^92^1158^2
+119 ;;^UTILITY(U,$J,358.3,25469,1,0)
+120 ;;=^358.31IA^4^2
